Current and future pharmacologic treatment of sarcopenia

Y Rolland; Graziano Onder; Je Morley; S Gillette Guyonet; G Abellan Van Kan; B. Vellas

doi:10.1016/j.cger.2011.03.008

Current and future pharmacologic treatment of sarcopenia

Y Rolland, Graziano Onder, Je Morley, S Gillette Guyonet, G Abellan Van Kan, B. Vellas

Research output: Contribution to journal › Article

59 Citations (Scopus)

Abstract

Sarcopenia is a complex multifactorial condition that can by treated with multimodal approaches. No pharmacologic agent to prevent or treat sarcopenia has been as efficacious as exercise (mainly resistance training) in combination with nutritional intervention (adequate protein and energy intake). However, performing resistance training sessions and following nutritional advice can be challenging, especially for frail, sarcopenic, elderly patients, and results remain only partial. Therefore, new pharmacologic agents may substantially reduce the functional decline in older people. This article reviews the new pharmacologic agents currently being assessed for treating sarcopenia.

Original language	English
Pages (from-to)	423-447
Number of pages	25
Journal	Clinics in Geriatric Medicine
Volume	27
DOIs	https://doi.org/10.1016/j.cger.2011.03.008
Publication status	Published - 2011

Keywords

Aged
Aging
Angiotensin-Converting Enzyme Inhibitors
Drug Therapy
Frail Elderly
Hormones
Humans
Muscle Weakness
Sarcopenia

Access to Document

10.1016/j.cger.2011.03.008

Cite this

@article{209a6dc6eb024a82a10b88ce59e86616,

title = "Current and future pharmacologic treatment of sarcopenia",

abstract = "Sarcopenia is a complex multifactorial condition that can by treated with multimodal approaches. No pharmacologic agent to prevent or treat sarcopenia has been as efficacious as exercise (mainly resistance training) in combination with nutritional intervention (adequate protein and energy intake). However, performing resistance training sessions and following nutritional advice can be challenging, especially for frail, sarcopenic, elderly patients, and results remain only partial. Therefore, new pharmacologic agents may substantially reduce the functional decline in older people. This article reviews the new pharmacologic agents currently being assessed for treating sarcopenia.",

keywords = "Aged, Aging, Angiotensin-Converting Enzyme Inhibitors, Drug Therapy, Frail Elderly, Hormones, Humans, Muscle Weakness, Sarcopenia, Aged, Aging, Angiotensin-Converting Enzyme Inhibitors, Drug Therapy, Frail Elderly, Hormones, Humans, Muscle Weakness, Sarcopenia",

author = "Y Rolland and Graziano Onder and Je Morley and {Gillette Guyonet}, S and {Abellan Van Kan}, G and B. Vellas",

year = "2011",

doi = "10.1016/j.cger.2011.03.008",

language = "English",

volume = "27",

pages = "423--447",

journal = "Clinics in Geriatric Medicine",

issn = "0749-0690",

publisher = "W.B. Saunders",

}

TY - JOUR

T1 - Current and future pharmacologic treatment of sarcopenia

AU - Rolland, Y

AU - Onder, Graziano

AU - Morley, Je

AU - Gillette Guyonet, S

AU - Abellan Van Kan, G

AU - Vellas, B.

PY - 2011

Y1 - 2011

N2 - Sarcopenia is a complex multifactorial condition that can by treated with multimodal approaches. No pharmacologic agent to prevent or treat sarcopenia has been as efficacious as exercise (mainly resistance training) in combination with nutritional intervention (adequate protein and energy intake). However, performing resistance training sessions and following nutritional advice can be challenging, especially for frail, sarcopenic, elderly patients, and results remain only partial. Therefore, new pharmacologic agents may substantially reduce the functional decline in older people. This article reviews the new pharmacologic agents currently being assessed for treating sarcopenia.

AB - Sarcopenia is a complex multifactorial condition that can by treated with multimodal approaches. No pharmacologic agent to prevent or treat sarcopenia has been as efficacious as exercise (mainly resistance training) in combination with nutritional intervention (adequate protein and energy intake). However, performing resistance training sessions and following nutritional advice can be challenging, especially for frail, sarcopenic, elderly patients, and results remain only partial. Therefore, new pharmacologic agents may substantially reduce the functional decline in older people. This article reviews the new pharmacologic agents currently being assessed for treating sarcopenia.

KW - Aged

KW - Aging

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Drug Therapy

KW - Frail Elderly

KW - Hormones

KW - Humans

KW - Muscle Weakness

KW - Sarcopenia

KW - Aged

KW - Aging

KW - Angiotensin-Converting Enzyme Inhibitors

KW - Drug Therapy

KW - Frail Elderly

KW - Hormones

KW - Humans

KW - Muscle Weakness

KW - Sarcopenia

UR - http://hdl.handle.net/10807/27419

U2 - 10.1016/j.cger.2011.03.008

DO - 10.1016/j.cger.2011.03.008

M3 - Article

SN - 0749-0690

VL - 27

SP - 423

EP - 447

JO - Clinics in Geriatric Medicine

JF - Clinics in Geriatric Medicine

ER -

Current and future pharmacologic treatment of sarcopenia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this